Crosslinked zwitterionic hydrogels

ABSTRACT

Zwitterionic crosslinking agents, crosslinked zwitterionic hydrogels prepared from copolymerization of zwitterionic monomers with the zwitterionic crosslinking agent, methods for making crosslinked zwitterionic hydrogels, and devices that include and methods that use the crosslinked zwitterionic hydrogels.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a continuation of International Application No.PCT/US2010/055875, filed Nov. 8, 2010, which claims the benefit of U.S.Patent Application No. 61/259,074, filed Nov. 6, 2009, each expresslyincorporated herein by reference in its entirety.

STATEMENT OF GOVERNMENT LICENSE RIGHTS

This invention was made with Government support under Contract Nos.N000140910137 and N000140711036 awarded by the Office of Naval Research.The Government has certain rights in the invention.

BACKGROUND OF THE INVENTION

Hydrogels have long been of interest for biological and biomaterialapplications due to their high water content that mimics theinterstitial tissue environment, ensures high diffusive permeability,and provides biomimetic mechanical strengths. Particular interest hasbeen given to PEG hydrogels and poly(2-hydroxyethyl methacrylate)(pHEMA) hydrogels because, in addition to the general properties ofhydrogels, they are also commonly considered be low fouling, bioinert,and versatile.

pHEMA hydrogels have found use in and been studied for applications suchas contact lenses, artificial cornea, drug delivery vehicles, cartilagesubstitutes, and tissue scaffolds, among others. The hydration of pHEMA,however, is lower than that of native tissue, and its fouling, whilelow, is higher than other nonfouling materials. Furthermore, pHEMAfunctionalization via the hydroxyl group is generally difficult.

PEG hydrogels are routinely used, and can only be modified forapplications that require a bioinert background with specific addedbioactive functionalities for controlled in vitro and in vivo uses whenadditional functional groups are introduced into PEG hydrogels. However,it has been found that PEG is subject to oxidation. The susceptibilityof PEG to oxidative damage reduces its utility for applications thatrequire long-term material stability. For applications in which maximalbiological stability and nonfouling are required, however, PEG-basedmaterials are insufficient.

Recently, zwitterionic compounds, including poly(carboxybetainemethacrylate) (pCBMA, Scheme 1, structure 1), have been demonstrated tobe ultra-low-fouling, meaning that surfaces coated with these polymersallow less than 5 ng/cm² protein adsorption. It was also demonstratedthat surfaces coated with zwitterionic poly(carboxybetaine methacrylate)greatly resist non-specific protein adsorption, even from undilutedblood plasma and serum and also prohibit long-term bacterialcolonization by Pseudomonas aeruginosa for up to 10 days at roomtemperature. The ultra-low-fouling of zwitterionic materials is due tohigh hydration around the opposing charges and the high energeticsrequired to remove that hydration layer. Furthermore, CBMA(carboxybetaine methacrylate) is functionalizable through conventionalEDC/NHS chemistry.

Because of the high hydration and ultralow fouling properties ofzwitterionic materials, zwitterionic hydrogels are of interest ashydrogels with superior suitability for biomedical applications. Lowprotein adhesion on sulfobetaine methacrylate (SBMA) and mixed chargehydrogels, and low cell adhesion on carboxybetaine methacrylate gels,have been demonstrated. The zwitterionic hydrogels studied so far,however, have shown low mechanical strength, which limits theirpotential biological uses. A need therefore exists for hydrogels havingimproved mechanical properties.

Another fundamentally limiting feature of these zwitterionic hydrogelsis the dearth of hydrophilic crosslinkers. The most commonly used of thecommercially available “hydrophilic” crosslinker isN,N′-methylenebis(acrylamide) (MBAA, Scheme 1, structure 2).Water-soluble at very low concentrations, this crosslinker is onlymoderately soluble at crosslinker concentrations around 10%, especiallyin the salt solutions that are ideal for zwitterionic hydrogelformation. Additionally problematic for polymerization with pSBMA andpCBMA is the inherent incompatibility of the polymerizable moieties: thegreatly different chemical structure of the crosslinker may result inpoor incorporation into the growing methacrylate polymer chains. Perhapsthe most unacceptable feature of MBAA as a crosslinker in zwitterionichydrogels is that it does not structure water the way the zwitterionicmonomers do. Structured water around the opposing charges in azwitterionic material provides the nonfouling mechanism; MBAA willdisrupt the ordered water and present locations where proteins,bacteria, and even cells, may bind and foul the hydrogel. Furthermore,the MBAA crosslinker is not functionalizable.

A need exists for crosslinked zwitterionic hydrogels that retain theadvantageous properties of non-crosslinked zwitterionic hydrogels. Thepresent invention seeks to fulfill this need and provides furtherrelated advantages.

SUMMARY OF THE INVENTION

The present invention provides a zwitterionic crosslinking agent,crosslinked zwitterionic hydrogels prepared from copolymerization ofzwitterionic monomers with the zwitterionic crosslinking agent, methodsfor making crosslinked zwitterionic hydrogels, and devices that includeand methods that use the crosslinked zwitterionic hydrogels.

In one aspect, the invention provides, a crosslinker having the formula:

wherein

R₁ and R₂ are independently selected from the group consisting ofhydrogen, fluorine, trifluoromethyl, C1-C6 alkyl, and C6-C12 arylgroups;

R₃ is selected from the group consisting of C1-C6 alkyl, C6-C12 aryl,CH₂═C(R₁)-L₁-, and CH₂═C(R₂)-L₂-;

L₁ and L₂ are independently selected from the group consisting of—C(═O)O—(CH₂)_(n)— and —C(═O)NH—(CH₂)_(n)—, wherein n is an integer from1 to 20;

L₃ is —(CH₂)_(n)—, where n is an integer from 1 to 20;

A₁ is C, S, SO, P, or PO;

X⁻ is the counter ion associated with the N⁺ cationic center; and

M⁺ is a counterion associated with the (A₁=O)O⁻ anionic center.

In one embodiment, A₁ is C or SO.

In another aspect, the invention provides a crosslinked hydrogel that iscrosslinked with the crosslinker of the invention. In one embodiment,the crosslinked hydrogel comprises a crosslinked polymer havingrepeating units and a plurality of crosslinks,

wherein each repeating unit has the formula:

wherein

R₄ is selected from the group consisting of hydrogen, fluorine,trifluoromethyl,

C1-C6 alkyl, and C6-C12 aryl groups;

R₅ and R₆ are independently selected from the group consisting of alkyland aryl, or taken together with the nitrogen to which they are attachedform a cationic center;

L₄ is a linker that covalently couples the cationic center [N⁺(R₅)(R₆)]to the polymer backbone [—(CH₂—CR₄)_(n)—];

L₅ is a linker that covalently couples the anionic center [A₂(=O)—O⁻] tothe cationic center;

A₂ is C, S, SO, P, or PO;

M⁺ is a counterion associated with the (A₂=O)O⁻ anionic center;

X⁻ is a counter ion associated with the cationic center;

n is an integer from 5 to about 10,000; and

wherein each crosslink has the formula:

wherein

R₁ and R₂ are independently selected from the group consisting ofhydrogen, fluorine, trifluoromethyl, C1-C6 alkyl, and C6-C12 arylgroups;

R₃ is selected from the group consisting of C1-C6 alkyl, C6-C12 aryl,CH₂═C(R₁)-L₁-, CH₂═C(R₂)-L₂-, or R₃ is the residual portion of a thirdcrosslink, -L₁-CR₁—CH₂— or -L₂-CR₂—CH₂—);

L₁ and L₂ are independently selected from the group consisting of—C(═O)O—(CH₂)_(n)— and —C(═O)NH—(CH₂)_(n)—, wherein n is an integer from1 to 20;

L₃ is —(CH₂)_(n)—, where n is an integer from 1 to 20;

A₁ is C, S, SO, P, or PO;

x is an integer from about 5 to about 10,000;

X⁻ is the counter ion associated with the N⁺ cationic center; and

M⁺ is a counterion associated with the (A=O)O⁻ anionic center.

In another embodiment, the crosslinked hydrogel comprises a crosslinkedpolymer having repeating, wherein each repeating unit has the formula:

wherein

R₇ and R₈ are independently selected from hydrogen, fluorine,trifluoromethyl, C1-C6 alkyl, and C6-C12 aryl groups;

R₉, R₁₀, and R₁₁ are independently selected from alkyl and aryl, ortaken together with the nitrogen to which they are attached form acationic center;

A₃(=O)—OM) is an anionic center, wherein A₃ is C, S, SO, P, or PO, and Mis a metal or organic counterion;

L₆ is a linker that covalently couples the cationic center[N⁺(R₉)(R₁₀)(R₁₁)] to the polymer backbone;

L₇ is a linker that covalently couples the anionic center [A(=O)—OM] tothe polymer backbone;

X⁻ is the counter ion associated with the cationic center;

n is an integer from 5 to about 10,000; and

p is an integer from 5 to about 10,000.

In another aspect, the invention provides a surface of a substrate,wherein the surface comprises crosslinked hydrogel of the invention.

DESCRIPTION OF THE DRAWINGS

The foregoing aspects and many of the attendant advantages of thisinvention will become more readily appreciated as the same become betterunderstood by reference to the following detailed description, whentaken in conjunction with the accompanying drawings.

FIG. 1 illustrates the chemical structures of a carboxybetaine monomer,carboxybetaine methacrylate (CBMA) (1), N,N′-methylenebis(acrylamide)(MBAA) (2), and carboxybetaine dimethacrylate (CBMAX) (3).

FIG. 2 is a schematic illustration of the synthesis of a representativezwitterionic crosslinker of the invention, carboxybetaine dimethacrylate(CBMAX) (3) and carboxybetaine dimethacrylate (CBMA3X) (4).

FIGS. 3A and 3B compare the hydration properties of representativezwitterionic crosslinked hydrogels of the invention, CBMAX-crosslinkedCBMA hydrogels (CBMAX), to MBAA-crosslinked CBMA hydrogels (MBAA):volume fraction (FIG. 3A), the amount by volume of polymer in a swollenhydrogel; and equilibrium water content (EWC) (FIG. 3B), the amount byweight of water in the swollen hydrogel, as a function of crosslinkercontent (%). Closed bars represent CBMAX-crosslinked CBMA hydrogels,while open bars represent MBAA-crosslinked CBMA hydrogels.

FIG. 4 compares relative cell adhesion as a function of crosslinkeramount (%) for CBMAX- and MBAA-crosslinked CBMA hydrogels. Cell adhesionof CBMA hydrogels normalized to the cell adhesion of pHEMA hydrogels.

FIG. 5 compares compression modulus (MPa) of CBMAX- and MBAA-crosslinkedCBMA hydrogels as a function of crosslinker content (%). Hydrogels werecompressed to failure, and the modulus reported was taken from the first10% strain. Closed diamonds represent CBMAX-crosslinked CBMA hydrogels,while open squares represent MBAA-crosslinked CBMA hydrogels.

FIGS. 6A and 6B compare physical properties of CBMAX- andMBAA-crosslinked CBMA hydrogels: crosslinking density (μmol/mm³) (FIG.6A) and mesh size (nm) (FIG. 6B), each as a function of crosslinkerconcentration (%), calculated from mechanical and swelling properties.Closed diamonds represent CBMAX-crosslinked CBMA hydrogels, while opensquares represent MBAA-crosslinked CBMA hydrogels.

FIG. 7 compares the hydration properties (EWC) as a function ofcrosslinker content (mol %) of representative zwitterionic crosslinkedpolymers of the invention, CBMA/CBMAX, prepared by photopolymerization.

FIG. 8 compares the compressive strength (MPa) as a function ofcrosslinker content (%) of representative zwitterionic crosslinkedpolymers of the invention, CBMA/CBMAX, prepared by photopolymerization.

FIG. 9 compares the compressive modulus (MPa) as a function ofcrosslinker content (%) of representative zwitterionic crosslinkedpolymers of the invention, CBMA/CBMAX, prepared by photopolymerization.

FIG. 10 is a schematic illustration of the preparation of arepresentative zwitterionic crosslinked hydrogel of the invention,CBMA/CBMAX, having a crosslinking gradient.

FIG. 11 compares the hydration properties (EWC) as a function ofcrosslinker concentration (%) of representative zwitterionic crosslinkedpolymers of the invention, CBMA/CBMAX, having a crosslinking gradient.

FIG. 12 compares the crosslinker density (μmol/mm³) as a function ofcrosslinker concentration (%) of representative zwitterionic crosslinkedpolymers of the invention, CBMA/CBMAX, having a crosslinking gradient.

FIG. 13 compares the compressive modulus (MPa) as a function ofcrosslinker concentration (%) of representative zwitterionic crosslinkedpolymers of the invention, CBMA/CBMAX, having a crosslinking gradient.

FIG. 14 compares the mesh size (nm) as a function of crosslinkerconcentration (%) of representative zwitterionic crosslinked polymers ofthe invention, CBMA/CBMAX, having a crosslinking gradient.

FIG. 15 is a photograph of representative CBMA/CBMAX gradient hydrogels:5-mm diameter disk (A) of 4% CBMA-X CBMA hydrogel and a square of 75%CBMAX-hydrogel (B) are shown compared to the representative gradienthydrogel (C) to illustrate the gradient by color that accompanies CBMAXcrosslinking.

FIG. 16 is graph illustrating crosslinker content (%) as a function ofdistance (cm) along a representative gradient hydrogel.

FIG. 17 compares water content (EWC) of representative CBMA/CBMAXhydrogels as a function of CBMAX content (0.1, 1, 10, and 20%).

FIGS. 18A-18H are images comparing COS-7 cell attachment onrepresentative CBMA/CBMAX hydrogels after a 3-day culture: hydrogelCBMAX content 0.1% before (FIG. 18A) and after GOx immobilization (FIG.18B), 1% hydrogels before (FIG. 18C) and after GOx immobilization (FIG.18D), 10% hydrogels before (FIG. 18E) and after GOx immobilization (FIG.18F), and 20% hydrogels before (FIG. 18G) and after GOx immobilization(FIG. 18H).

FIGS. 19A-19D compare current response (nA) of glucose sensors coatedwith representative CBMA/CBMAX hydrogels as a function of glucoseconcentration (mM) in PBS at 1, 10, 25, and 40 days: hydrogel CBMAXcontent 0.1% (FIG. 19A), 1% (FIG. 19B), 10% (FIG. 19C), and 20% (FIG.19D). Operating potential: +0.75 V vs. Ag/AgCl reference electrode.

FIGS. 20A-20D compare current response (nA) of glucose sensors coatedwith representative CBMA/CBMAX hydrogels as a function of glucoseconcentration (mM) in 100% blood serum at 1, 10, 25, and 40 days:hydrogel CBMAX content 0.1% (FIG. 20A), 1% (FIG. 20B), 10% (FIG. 20C),and 20% (FIG. 20D). Operating potential: +0.75 V vs. Ag/AgCl referenceelectrode.

FIG. 21 compares hydrodynamic size of OA-GNPs, OC-GNPs, CA-GNPs, andCC-GNPs in undiluted blood serum. Serum proteins are removed bycentrifuge and redispersed in PBS before measurement.

FIG. 22 compares hydronamic size of OA-GNPs, OC-GNPs, CA-GNPs, andCC-GNPs mixed with undiluted blood serum.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a zwitterionic crosslinking agent,crosslinked zwitterionic hydrogels prepared from copolymerization ofzwitterionic monomers with the zwitterionic crosslinking agent, methodsfor making crosslinked zwitterionic hydrogels, and devices that includeand methods that use the crosslinked zwitterionic hydrogels.

Zwitterionic Crosslinking Agent

In one aspect, the invention provides a zwitterionic crosslinking agent.The zwitterionic crosslinking agent can be copolymerized with suitablepolymerizable monomers and comonomers to provide crosslinked polymersand crosslinked copolymers.

The zwitterionic crosslinking agent is advantageously used to preparecrosslinked polymers and crosslinked copolymers, such as crosslinkedhydrogels, by copolymerization with one or more zwitterionic monomers,or by copolymerization with one or more charged comonomers, such as ionpair comonomers.

The zwitterionic crosslinking agent of the invention has formula (I):

wherein

R₁ and R₂ are independently selected from hydrogen, fluorine,trifluoromethyl, C1-C6 alkyl, and C6-C12 aryl groups;

R₃ is selected from C1-C6 alkyl, C6-C12 aryl, CH₂═C(R₁)-L₁-, orCH₂═C(R₂)-L₂-;

L₁ and L₂ are independently selected from the group consisting of—C(═O)O—(CH₂)_(n)— and —C(═O)NH—(CH₂)_(n)—, wherein n is an integer from1 to 20;

L₃ is —(CH₂)_(n)—, where n is an integer from 1 to 20; and

A₁ is C, S, SO, P, or PO;

X⁻ is the counter ion associated with the N⁺ cationic center; and

M⁺ is a metal or organic counterion associated with the (A=O)O⁻ anioniccenter.

In one embodiment, R₁, R₂, and R₃ are C1-C3 alkyl. In one embodiment,R₁, R₂, and R₃ are methyl.

In one embodiment, L₁ and L₂ are —C(═O)O—(CH₂)_(n)—, wherein n is 1-6.In one embodiment, L₁ and L₂ are —C(═O)O—(CH₂)₂—.

In one embodiment, L₃ is —(CH₂)_(n)—, wherein n is 1-6. In oneembodiment, L₃ is —(CH₂)—.

In one embodiment, A₁ is C. In one embodiment, A₁ is SO.

FIG. 1 illustrates the chemical structure of a representativezwitterionic crosslinking agent of the invention, see Compound 3,referred to herein as CBMAX. The preparation of a representativezwitterionic crosslinking agent of the invention, CBMAX, is described inExample 1 and illustrated schematically in FIG. 2.

Crosslinked Zwitterionic Hydrogels

In another aspect, the invention provides crosslinked zwitterionichydrogels prepared from copolymerization of zwitterionic monomers withthe zwitterionic crosslinking agent. The zwitterionic crosslinking agentcan be copolymerized with suitable polymerizable monomers and comonomersto provide crosslinked polymers and crosslinked copolymers.

The crosslinked hydrogels of the invention are crosslinked polymershaving repeating groups and crosslinks derived from the zwitterioniccrosslinking agent.

Zwitterionic Monomers. In one embodiment, the crosslinked hydrogels ofthe invention are crosslinked polymers prepared from copolymerization ofthe zwitterionic crosslinking agent and suitable polymerizablezwitterionic monomers. In this embodiment, the crosslinked polymer(e.g., hydrogel) has repeating units having formula (II):

wherein

R₄ is selected from hydrogen, fluorine, trifluoromethyl, C1-C6 alkyl,and C6-C12 aryl groups;

R₅ and R₆ are independently selected from alkyl and aryl, or takentogether with the nitrogen to which they are attached form a cationiccenter;

L₄ is a linker that covalently couples the cationic center [N⁺(R₅)(R₆)]to the polymer backbone [—(CH₂—CR₄)_(n)—];

L₅ is a linker that covalently couples the anionic center [A₂(=O)O⁻] tocationic center;

A₂ is C, S, SO, P, or PO;

M⁺ is a metal or organic counterion associated with the (A₂=O)O⁻ anioniccenter;

X⁻ is the counter ion associated with the cationic center;

n is an integer from 5 to about 10,000; and

* represents the point at which the repeating unit is covalently linkedto either an adjacent repeating unit or the zwitterionic crosslink.

In one embodiment, R₄ is C1-C3 alkyl.

R₅ and R₆ are independently selected from alkyl and aryl, or takentogether with the nitrogen to which they are attached form a cationiccenter. In one embodiment, R₅ and R₆ are C1-C3 alkyl.

In certain embodiments, L₄ is selected from the group consisting of—C(═O)O—(CH₂)_(n)— and —C(═O)NH—(CH₂)_(n)—, wherein n is an integer from1 to 20. In certain embodiments, L₄ is —C(═O)O—(CH₂)_(n)—, wherein n is1-6.

In certain embodiments, L₅ is —(CH₂)_(n)—, where n is an integer from 1to 20.

In certain embodiments, A₂ is C or SO.

In certain embodiments, n is an integer from 5 to about 5,000.

In one embodiment, R₄, R₅, and R₆ are methyl, L₄ is —C(═O)O—(CH₂)₂—, L₅is —(CH₂)—, A₁ is C, and n is an integer from 10 to about 1,000.

In addition to the crosslinked polymer (e.g., hydrogel) having repeatingunits having formula (II) above, the crosslinked polymer includeszwitterionic crosslinks having formula (III):

wherein R₁, R₂, R₃, L₁, L₂, L₃, A₁, X⁻, and M⁺ are as described abovefor the zwitterionic crosslinking agent (formula (I), and x is aninteger from about 5 to about 10,000. For the crosslinked hydrogel whereR₃ includes a polymerizable group, the hydrogel is further crosslinkedthrough R₃, as shown above (-L₁-CR₁—CH₂— and -L₂-CR₂—CH₂—).

The crosslinked zwitterionic hydrogels of the invention can be preparedby copolymerization of the zwitterionic crosslinking agent with monomershaving formula (IV):CH₂═C(R₄)-L₄-N⁺(R₅)(R₆)-L₅-A₂(=O)O⁻M⁺X⁻  (IV)wherein R₄, R₅, R₆, L₄, L₅, A₂, X⁻, and M⁺ are as described above forthe repeating unit of formula (II).

Representative crosslinked zwitterionic polymers of the invention haveformula (V):PB-(L₄-N⁺(R₅)(R₆)-L₅-A₂(=O)O⁻M⁺)_(n)(X⁻)_(n)  (V)wherein R₅, R₆, L₄, L₅, A₂, X⁻, M⁺, and n are as described above for therepeating unit of formula (II), and PB is the polymer backbone thatincludes repeating units [formula (II)] and crosslinks [formula (III)].

The preparation and characteristics of a representative crosslinkedzwitterionic hydrogel of the invention, CBMA/CBMAX, is described inExample 2.

Crosslinked Mixed Charge Hydrogels

In another aspect, the invention provides crosslinked mixed chargecopolymers (or hydrogels) prepared from copolymerization of ion paircomonomers with the zwitterionic crosslinking agent.

As used herein, the term “mixed charge copolymer (or hydrogel)” refersto a copolymer having a polymer backbone, a plurality of positivelycharged repeating units, and a plurality of negatively charged repeatingunits. In the practice of the invention, these copolymers may beprepared by polymerization of an ion-pair comonomer.

The mixed charge copolymer includes a plurality of positively chargedrepeating units, and a plurality of negatively charged repeating units.In one embodiment, the mixed charge copolymer is substantiallyelectronically neutral. As used herein, the term “substantiallyelectronically neutral” refers to a copolymer that imparts advantageousnonfouling properties to the copolymer. In one embodiment, asubstantially electronically neutral copolymer is a copolymer having anet charge of substantially zero (i.e., a copolymer about the samenumber of positively charged repeating units and negatively chargedrepeating units). In one embodiment, the ratio of the number ofpositively charged repeating units to the number of the negativelycharged repeating units is from about 1:1.1 to about 1:0.5. In oneembodiment, the ratio of the number of positively charged repeatingunits to the number of the negatively charged repeating units is fromabout 1:1.1 to about 1:0.7. In one embodiment, the ratio of the numberof positively charged repeating units to the number of the negativelycharged repeating units is from about 1:1.1 to about 1:0.9.

Ion Pair Comonomers.

In one embodiment, the crosslinked hydrogels of the invention arecrosslinked polymers prepared from copolymerization of the zwitterioniccrosslinking agent and suitable polymerizable ion pair comonomers.

Representative ion-pair comonomers useful in the invention have formulas(VI) and (VII):CH₂═C(R₇)-L₆-N⁺(R₉)(R₁₀)(R₁₁)X⁻  (VI)CH₂═C(R₈)-L₇-A₃(=O)—OM  (VII)

In this embodiment, the crosslinked polymer (e.g., hydrogel) hasrepeating units having formula (VIII):

wherein

R₇ and R₈ are independently selected from hydrogen, fluorine,trifluoromethyl, C1-C6 alkyl, and C6-C12 aryl groups;

R₉, R₁₀, and R₁₁ are independently selected from alkyl and aryl, ortaken together with the nitrogen to which they are attached form acationic center;

A₃(=O)—OM) is an anionic center, wherein A₃ is C, S, SO, P, or PO, and Mis a metal or organic counterion;

L₆ is a linker that covalently couples the cationic center[N⁺(R₉)(R₁₀)(R₁₁)] to the polymer backbone;

L₇ is a linker that covalently couples the anionic center [A(=O)—OM] tothe polymer backbone;

X⁻ is the counter ion associated with the cationic center;

n is an integer from 5 to about 10,000;

p is an integer from 5 to about 10,000; and

* represents the point at which the repeating units is covalently linkedto either and adjacent repeating unit or the zwitterionic crosslink.

In one embodiment, R₇ and R₈ are C1-C3 alkyl.

R₉, R₁₀, and R_(H) are independently selected from alkyl and aryl, ortaken together with the nitrogen to which they are attached form acationic center. In one embodiment, R₉, R₁₀, and R₁₁ are C1-C3 alkyl.

In certain embodiments, L₆ is selected from the group consisting of—C(═O)O—(CH₂)_(n)— and —C(═O)NH—(CH₂)_(n)—, wherein n is an integer from1 to 20. In certain embodiments, L₆ is —C(═O)O—(CH₂)_(n)—, wherein n is1-6.

In certain embodiments, L₇ is a C1-C20 alkylene chain. Representative L₇groups include —(CH₂)_(n)—, where n is 1-20 (e.g., 1, 3, or 5)

In certain embodiments, A₃ is C, S, SO, P, or PO.

In certain embodiments, n is an integer from 5 to about 5,000.

In one embodiment, R₇, R₈, R₉, R₁₀, and R₁₁ are methyl, L₆ and L₇ are—C(═O)O—(CH₂)₂—, A₁ is C, and n is an integer from 10 to about 1,000.

In addition to the crosslinked copolymer (e.g., hydrogel) havingrepeating units having formula (VIII) above, the crosslinked polymerincludes zwitterionic crosslinks having formula (III).

Representative crosslinked zwitterionic polymers of the invention haveformula (IX):PB-[L₆-N⁺(R₉)(R₁₀)(R₁₁)]_(n)[L₇-A₃(=O)—O⁻M⁺)]_(p)(X⁻)_(n)  (IX)wherein L₆, N⁺(R₉)(R₁₀)(R₁₁), L₇, A₃(=O)OM, X⁻, n, and p are asdescribed above, and PB is the polymer backbone that includes repeatingunits [formula (VIII)] and crosslinks [formula (III)].

The following is a description of the crosslinking agent, monomers,comonomers, polymers, copolymers, and crosslinks of formulas (I)-(IX)described above.

In the above formulas, PB is the polymer backbone. Representativepolymer backbones include vinyl backbones (e.g.,—C(R′)(R″)—C(R″′)(R″″)—, where R′, R″, R″′, and R″′ are independentlyselected from hydrogen, alkyl, and aryl) derived from vinyl monomers(e.g., acrylate, methacrylate, acrylamide, methacrylamide, styrene).Other suitable backbones include polymer backbones that provide forpendant groups. Other representative polymer backbones include peptide(polypeptide), urethane (polyurethane), and epoxy backbones.

Similarly, in the above formulas, CH₂═C(R)— is the polymerizable group.It will be appreciated that other polymerizable groups, including thosenoted above, can be used to provide the monomers and polymers of theinvention.

In the above formulas, N⁺ is the cationic center. In certainembodiments, the cationic center is a quaternary ammonium (e.g., Nbonded to L₄, R₅, R₆, and L₅). In addition to ammonium, other usefulcationic centers (R₅ and R₆ taken together with N) include imidazolium,triazaolium, pyridinium, morpholinium, oxazolidinium, pyrazinium,pyridazinium, pyrimidinium, piperazinium, and pyrrolidinium.

R₄, R₅, R₆, R₉, R₁₀, and R₁₁ are independently selected from hydrogen,alkyl, and aryl groups. Representative alkyl groups include C1-C10straight chain and branched alkyl groups. In certain embodiments, thealkyl group is further substituted with one of more substituentsincluding, for example, an aryl group (e.g., —CH₂C₆H₅, benzyl).Representative aryl groups include C6-C12 aryl groups including, forexample, phenyl. For certain embodiments of the above formulas, R₅ andR₆, or R₉, R₁₀, and R₁₁ are taken together with N⁺ form the cationiccenter.

L₄ (or L₆) is a linker that covalently couples the cationic center tothe polymer backbone. In certain embodiments, L₄ includes a functionalgroup (e.g., ester or amide) that couples the remainder of L₄ to thepolymer backbone (or polymerizable moiety for the monomers). In additionto the functional group, L₄ can include an C1-C20 alkylene chain.Representative L₄ groups include —C(═O)O—(CH₂)_(n)— and—C(═O)NH—(CH₂)_(n)—, where n is 1-20 (e.g., 3).

L₅ is a linker that covalently couples the cationic center to theanionic group (i.e., (A=O)O⁻). L₅ can be a C1-C20 alkylene chain.Representative L₅ groups include —(CH₂)_(n)—, where n is 1-20 (e.g., 1,3, or 5).

L₇ is a linker that covalently couples the polymer backbone to theanionic group. L₇ can be a C1-C20 alkylene chain. Representative L₇groups include —(CH₂)_(n)—, where n is 1-20 (e.g., 1, 3, or 5).

A(=O)—O⁻ is the anionic center. The anionic center can be a carboxylicacid ester (A is C), a sulfinic acid (A is S), a sulfonic acid (A isSO), a phosphinic acid (A is P), or a phosphonic acid (A is PO).

In the above formulas, representative alkyl groups include C1-C30straight chain and branched alkyl groups. In certain embodiments, thealkyl group is further substituted with one of more substituentsincluding, for example, an aryl group (e.g., —CH₂C₆H₅, benzyl).

Representative aryl groups include C6-C12 aryl groups including, forexample, phenyl including substituted phenyl groups (e.g., benzoicacid).

X⁻ is the counter ion associated with the cationic center. The counterion can be the counter ion that results from the synthesis of thecationic polymers or the monomers (e.g., Cl⁻, Br⁻, I⁻). The counter ionthat is initially produced from the synthesis of the cationic center canalso be exchanged with other suitable counter ions to provide polymershaving controllable hydrolysis properties and other biologicalproperties. Representative hydrophobic counter ions includecarboxylates, such as benzoic acid and fatty acid anions (e.g.,CH₃(CH₂)_(n)CO₂ ⁻ where n=1-19); alkyl sulfonates (e.g., CH₃(CH₂)_(n)SO₃⁻ where n=1-19); salicylate; lactate; bis(trifluoromethylsulfonyl)amideanion (N⁻(SO₂CF₃)₂); and derivatives thereof. Other counter ions alsocan be chosen from chloride, bromide, iodide, sulfate; nitrate;perchlorate (ClO₄); tetrafluoroborate (BF₄); hexafluorophosphate (PF₆);trifluoromethylsulfonate (SO₃CF₃); and derivatives thereof. Othersuitable counter ions include hydrophobic counter ions and counter ionshaving therapeutic activity (e.g., an antimicrobial agent, such assalicylic acid (2-hydroxybenzoic acid), benzoate, lactate.

For the monomers, R₁ and R₂ [formula (I)] and R₄ [formula (IV)], isselected from hydrogen, fluoride, trifluoromethyl, and C1-C6 alkyl(e.g., methyl, ethyl, propyl, butyl). In one embodiment, R₁, R₂, and R₄are hydrogen. In one embodiment, R₁, R₂, and R₄ are methyl.

Surfaces Treated with Crosslinked Zwitterionic Hydrogels

In another aspect, the invention provides surfaces that have beentreated with crosslinked zwitterionic hydrogels. The crosslinkedzwitterionic hydrogels of the invention, hydrolyzable to zwitterionicpolymers, can be advantageously used as coatings for the surfaces of avariety of devices including, for example, medical devices.

The hydrogels of the invention are advantageously used to coat surfacesto provide biocompatible, antimicrobial, and nonfouling surfaces.Accordingly, in another aspect, the invention provides devices andmaterials having a surface (i.e., one or more surfaces) to which havebeen applied (e.g., coated, covalently coupled, ionically associated,hydrophobically associated) one or more crosslinked zwitterionichydrogels of the invention. Representative devices and carriers that maybe advantageously treated with a hydrogel of the invention, modified toinclude a hydrogel of the invention, or incorporates a hydrogel of theinvention include:

particle (e.g., nanoparticle) having a surface treated with, modified toinclude, or incorporates a hydrogel of the invention;

drug carrier having a surface treated with, modified to include, orincorporates a material of the invention;

non-viral gene delivery system having a surface treated with, modifiedto include, or incorporates a hydrogel of the invention;

biosensor having a surface treated with, modified to include, orincorporates a hydrogel of the invention;

devices for bioprocesses or bioseparations, such as membranes formicrobial suspension, hormone separation, protein fractionation, cellseparation, waste water treatment, oligosaccharide bioreactors, proteinultrafiltration, and diary processing having a surface treated with,modified to include, or incorporates a hydrogel of the invention;

implantable sensor having a surface treated with, modified to include,or incorporates a hydrogel of the invention;

subcutaneous sensor having a surface treated with, modified to include,or incorporates by a hydrogel of the invention;

implant, such as a breast implant, cochlear implant, and dental implanthaving a surface treated with, modified to include, or incorporates ahydrogel of the invention;

contact lens having a surface treated with, modified to include, orincorporates a hydrogel of the invention;

tissue scaffold having a surface treated with, modified to include, orincorporates a hydrogel of the invention;

implantable medical devices, such as an artificial joint, artificialheart valve, artificial blood vessel, pacemaker, left ventricular assistdevice (LVAD), artery graft, and stent having a surface treated with,modified to include, or incorporates a hydrogel of the invention; and

medical devices, such as an ear drainage tube, feeding tube, glaucomadrainage tube, hydrocephalous shunt, keratoprosthesis, nerve guidancetube, urinary catheter, tissue adhesive, and x-ray guide having asurface treated with, modified to include, or incorporates by a hydrogelof the invention.

Other representative substrates and surfaces that may be advantageouslytreated with a hydrogel of the invention, modified to include a hydrogelof the invention, or incorporates a hydrogel of the invention includefabrics and such as in clothing (e.g., coats, shirts, pants,undergarments, including such as worn by hospital and militarypersonnel), bedding (e.g., blankets, sheets, pillow cases, mattresses,and pillows), toweling, and wipes.

Other representative substrates and surfaces that may be advantageouslytreated with a hydrogel of the invention, modified to include a hydrogelof the invention, or incorporates a hydrogel of the invention includeworking surfaces such as tabletops, desks, and countertops.

The following is a description of a representative zwitterioniccrosslinked hydrogel of the invention (CBMA/CBMAX).

As noted above, the invention provides a zwitterionic crosslinker toimprove the mechanical properties of nonfouling pCBMA hydrogels withoutthe use of a fouling crosslinker. The structure of a representativezwitterionic crosslinker, a CBMA-based dimethacrylate crosslinker(CBMAX) is shown in FIG. 1, structure 3. The crosslinked has a chemicalstructure is identical to the CBMA monomer except that there is a onecarbon spacer between the cationic quaternary amine and the anioniccarboxyl group instead of two, and that one of the two methyl groups onthe quaternary amine is replaced by a second methacrylate group. Thecrosslinker exhibits excellent solubility in 1M salt solutions, and itszwitterionic group ensures that, unlike MBAA, it will provide continuityof structured water across the crosslinks in a pCBMA hydrogel. The waterstructure of zwitterionic phosphorylcholine (PC)-based hydrogels madewith a custom-made phosphorylcholine-based crosslinker was studied and aqualitative difference in the water in PC-crosslinked zwitterionichydrogels compared to MBAA-crosslinked zwitterionic hydrogels wasobserved (Goda T, Watanabe J, Takai M, Ishihara K. Water structure andimproved mechanical properties of phospholipid polymer hydrogel withphosphorylcholine centered intermolecular cross-linker. Polymer 2006;47:1390-1396; and Goda T, Matsuno R, Konno T, Takai M, Ishihara K.Protein adsorption resistance and oxygen permeability of chemicallycrosslinked phospholipid polymer hydrogel for ophthalmologicbiomaterials. J Biomed Mater Res B Appl Biomater 2009; 89:184-190).Hydrogels made from zwitterionic monomers and zwitterionic crosslinkershad more ice-like bound water than hydrogels made from zwitterionicmonomers and MBAA, and the improved mechanical properties of thezwitterionically crosslinked zwitterionic hydrogels was attributed tothe increased order of the water.

The preparation of a representative zwitterionic crosslinker of theinvention, 1-carboxy-N-methyl-N-di(2-methacryloyloxy-ethyl)methanaminiuminner salt (CBMX), is described in Example 1. The preparation isillustrated in FIG. 2

The preparation of a representative zwitterionic crosslinked hydrogel ofthe invention (CBMA/CBMAX) is described in Example 2.

The preparation and properties of representative zwitterioniccrosslinked hydrogels of the invention, CBMA/CBMAX, prepared byphotopolymerization are described in Example 3.

The preparation and properties of representative zwitterioniccrosslinked hydrogels of the invention, CBMA/CBMAX, prepared byphotopolymerization and having crosslinking gradients are described inExample 4.

The use of a representative zwitterionic crosslinked hydrogel of theinvention, CBMA/CBMAX, in a glucose biosensor is described in Example 5.

Hydration Properties of CBMA Hydrogels with CBMAX

Because the high water content of hydrogels often minors the watercontent of biological tissues, hydrogels are attractive for biologicalapplications. The swelling properties of CBMA hydrogels were calculatedusing equations (1) and (2): the mass and dimensions of hydrogel disksbefore and after dehydration were used to calculate the equilibriumwater content and volume fraction of gels, respectively. FIGS. 3A and 3Bshow the equilibrium water content (FIG. 3A) and volume fraction (FIG.3B) measured for MBAA-crosslinked hydrogels up to the solubility limitat 17% crosslinker and for CBMA-crosslinked hydrogels from 2% CBMAX to100% CBMAX (open and closed bars, respectively). As expected, anincrease in crosslinker content results in a decrease of hydration andswelling. At 100% CBMAX, hydration fell to about 60% equilibrium watercontent, a value that is remarkably high for such a large amount ofcrosslinking.

As these figures show, there appears to be no difference in watercontent when the CBMA is crosslinked with CBMAX or with MBAA.

Nonfouling Properties of CBMA Hydrogels with CBMAX

CBMA hydrogels made with 4% CBMAX, 4% MBAA, 17% CBMAX, and 17% MBAA, andCBMAX hydrogels, were tested for nonfouling. The low crosslinker contentwas chosen because it is the lowest that is practically handled, whilethe 17% crosslinker hydrogels were chosen because 17% is the upper limitof MBAA incorporation; this composition was expected to most clearlydemonstrate any difference between the fouling properties of these twohydrogels. Fibroblast (COS-7) cells were seeded on antibiotic-sterilizedhydrogels and allowed to grow for three days in supplemented growthmedium. On the third day, cell adhesion was quantified visually: fifteenmicroscopy images of each hydrogel formulation were collected, and theabsolute numbers of cells adhered to the gels were counted.

The number of cells adhered to hydrogels of each formulation arecompared quantitatively in FIG. 4, as a function of crosslinker content,and normalized to the number of cells adhered to pHEMA hydrogels. Solidbars represent CBMAX-crosslinked hydrogels, while open bars representMBAA-crosslinked hydrogels. The rightmost bar represents the control,pHEMA hydrogel. All CBMA hydrogels show a significant decrease (about80-90%) in cell adhesion relative to low fouling pHEMA, especially insupplemented growth medium. pHEMA itself exhibits only a small percentof the cell adhesion on TCPS.

At low crosslinker content, both CBMAX- and MBAA-crosslinked hydrogelshave very little fouling, about 10-15% that of pHEMA hydrogels (samewithin error). At higher crosslinker content there is a noticeabledivergence: CBMAX-crosslinked hydrogels remain very nonfouling (about10% that of pHEMA), while the fouling of MBAA-crosslinked hydrogels hasworsened (to about 20% that of pHEMA). Furthermore, even 100% CBMAXhydrogels demonstrate the same low fouling levels of the lightlycrosslinked CBMA hydrogels (about 10% that of pHEMA hydrogels). Thus,MBAA incorporation corrupts the nonfouling properties of CBMA hydrogels,possibly by disrupting the ordered water around the zwitterionic polymerchains, whereas the CBMA crosslinker provides continuity of chemistryand hydration of the molecular level, and thereby preserves thenonfouling properties within CBMA hydrogels. These results weresupported by measuring the nonspecific protein adsorption via ELISA.

RGD-Functionalization of CBMA Hydrogels

Similar to the nonfouling study described above, CBMA hydrogels madeusing 17% CBMAX and 17% MBAA hydrogels demonstrate their ability forfunctionalization. The hydrogels were post-functionalized with cRGD, acell-binding motif found on all integrins, using traditionalEDC/sulfoNHS chemistry. Identical chemistry without EDC was performed oncontrol hydrogels. COS-7 cells were then seeded on theEDC/sulfoNHS-cRGD-treated hydrogels, and on the sulfoNHS-cRGD-treatedcontrol hydrogels. The cell cultures were allowed to grow for 3 days,after which time cell proliferation was quantified with lightmicroscopy. Fifteen pictures were taken of each hydrogel formulation,and the absolute numbers of cells adhered to the gels were counted. Theresults are summarized in Table 1.

TABLE 1 Cell adhesion on 17% CBMAX- and MBAA-crosslinked hydrogelsfunctionalized with cRGD. Nonspecific protein adsorption from ELISAreflects nonspecific cell adhesion on pre-functionalized hydrogels.Protein Adsorption Cell Adhesion Nonspecific Cells Adhered Cells AdheredProtein Adsorption Before After Crosslinker (ELISA, FunctionalizationFunctionalization (17%) absorbance) (abs. no./Frame) (abs. no./Frame)CBMAX 0.07 ± 0.03  2 ± 1 16 ± 3 MBAA 0.79 ± 0.02 10 ± 2 25 ± 3

As shown in Table 1, both functionalized CBMAX- and MBAA-crosslinkedhydrogels exhibit an increase in cell adhesion. Nonspecifically adheredproteins from the supplemented medium will foul a surface and facilitatenonspecific cell adhesion. As shown by ELISA, CBMAX-crosslinkedhydrogels resist nonspecific protein adsorption much more effectivelythan do MBAA-crosslinked hydrogels, and this is reflected in the loweroverall number of cells adhered to the CBMAX-crosslinked hydrogels. Thehigher absolute numbers of adhered cells on 17% MBAA-crosslinkedhydrogels, reflects the higher nonspecific cell adhesion, or fouling,that results from the presence of the MBAA. Both hydrogels arefunctionalized with cRGD to induce specific cell adhesion anddemonstrate controlled biocompatibility. However, CBMAX-crosslinkedhydrogels display lower levels of background nonspecific cell adhesion.

Mechanical Properties of CBMA Hydrogels

Mechanical properties are a major challenge for highly hydratedhydrogels. In general, the more water in the hydrogel, the weaker thestructure. In order to function effectively as a mimic for biologicaltissue and to provide a conducive environment for cell growth, hydrogelsshould be “soft”. Practically, however, mechanical strength is requiredfor handling. Furthermore, substrate stiffness plays an important rolein cell fate and stem cell differentiation.

Hydrogel disks were compressed to failure, and the extracted compressiveYoung's Moduli are shown in FIG. 5 as a function of crosslinkercomposition (CBMAX versus MBAA, represented by closed diamonds and opensquares, respectively) and content (by % crosslinker). These values arealso tabulated in Table 2.

TABLE 2 Mechanical properties of CBMAX- and MBAA-crosslinked CBMAhydrogels. Modulus, break strain, and break stress, were extracted fromstress-strain curves of CBMA hydrogels under compression. CrosslinkerModulus (MPa) Break strain (%) Break stress (MPa) content (%) MBAA CBMAXMBAA CBMAX MBAA CBMAX 4 0.20 ± 0.03 0.6 ± 0.1 40 30 0.06 0.1 9 0.57 ±0.03 1.11 ± 0.06 45 25 0.3 0.4 17 0.65 ± 0.06 1.79 ± 0.09 30 30 0.3 0.633 — 4.1 ± 0.6 — 25 — 0.6 50 — 5.5 ± 0.3 — 20 — 1 75 — 6.44 ± 0.02 — 15— 1 100 — 8.2 ± 0.5 — 45 — 2.5

At the crosslinker concentrations for which CBMAX- and MBAA-crosslinkedhydrogels can be directly compared (4%, 9%, and 17%), theCBMAX-crosslinked hydrogels demonstrated improved mechanical properties.The compressive modulus of CBMAX-crosslinked hydrogels is greater thanthat of MBAA-crosslinked hydrogels at all concentrations accessible toboth crosslinkers, and the break stress is greater at all concentrationsas well. Higher crosslinker content is accessible with CBMAX. At 100%CBMAX, the compressive modulus reaches 8 MPa, an impressive value for ahydrogel with relatively high water content (60%), and one that placesthis material well within the range of articular cartilage. This alsocompares favorably to pHEMA hydrogels (compressive modulus of 0.6 MPa)and even to PEG hydrogels (compressive modulus up to about 3 MPa with50% crosslinker water content).

Because no difference in the equilibrium water content of CBMA hydrogelswith CBMAX versus CBMA hydrogels with MBAA crosslinker was found, theseimproved mechanical properties cannot be attributed to decreasedhydration, but rather to a difference in the quality of the waterstructure.

The compression data demonstrates the linear nature of the relationshipbetween the amount of crosslinker and the compressive modulus of theCBMA-CBMAX hydrogels. When compressive modulus is plotted as a functionof crosslinker content from 4% crosslinker to 100% CBMAX (FIG. 5), therelationship is linear, and a regression of 0.9616. This underlines thecompatibility of the gel system: the crosslinker is uniformlyincorporated into the growing linear polymer chains at low crosslinkercompositions, and, at the other end of the scale, the monomer isuniformly incorporated into the highly crosslinked network at highcrosslink compositions. Thus, the hydrogel structure is morehomogeneous. The MBAA crosslinker, on the other hand, showed poorerintegration into the growing polymer chains, as evidenced by the lesslinear (R²=0.8562) relationship between crosslinker composition andcompressive modulus. Increasing the crosslinker content from 9% to 17%only marginally improved the mechanical properties of the gel, due tolimited solubility even at this low concentration, and to poorincorporation of the dissolved crosslinker into the growing linear CBMApolymers. The microscopic structural defects that appear ininhomogeneous hydrogel networks compromise the mechanical integrity ofthe macroscopic hydrogel.

Physical Properties of CBMA Hydrogels

Using the hydration data and stress-stain curves collected above,equations 3 and 4 were used to calculate some physical properties ofCBMA hydrogels when crosslinked with MBAA or CBMAX. Specifically, thestress-strain curves are manipulated to stress vs. (α−α⁻²) curves, whereα is the ratio of the deformed length to the original length. At lowstrains, this relationship is linear, and the crosslinking density canbe extracted from the slope of this line (see equation 3). Then,converting the number of crosslinks per volume to the volume per singlecrosslinker yields the distance between two crosslinks. These calculatedvalues of crosslinker density and mesh size, as a function ofcrosslinking composition and content, are shown in FIGS. 6A and 6B,respectively. It can be seen that at the same nominal crosslinkercontent, the crosslinking densities of MBAA-crosslinked hydrogels islower than that of CBMAX-crosslinked hydrogels, reinforcing thehypothesis that MBAA is less compatible with the CBMA monomer and thusthe acrylamides of the MBAA incorporate poorly into the growingmethacrylate polymer chains. On the other hand, the higher crosslinkerdensity of the CBMAX-crosslinked hydrogels suggests better compatibilityand more uniform incorporation of the CBMAX methacrylates into thegrowing methacrylate polymer. The mesh sizes calculated from thecrosslinker density values tell a similar story, and further support theidea that the difference in the monomer-crosslinker compatibility playsa major role in the difference in the mechanical properties of theCBMA-CBMAX and CBMA-MBAA systems.

Additionally, due to its excellent solubility and copolymerization withthe CBMA monomer, the CBMAX-crosslinked hydrogels have access to a widerrange of formulations, which provides greater diversity of physicalproperties. The different crosslinking densities, and thus differentpore sizes, that arise in a controlled manner with CBMAX-crosslinkedhydrogels afford yet another means of biological manipulation. Hydrogelsare prized for their biomimetic structure: high water content and poresthat allow passage of biomolecules. Pores ranging in size from <2 nm forsmall molecules such as sugars and growth factors, to pores>10 nm forbiomacromolecules such as large proteins and antibodies render allaccessible to incorporation into hydrogels. By controlling thecrosslinker content, the pore size of the hydrogels can be controlledwithout compromising nonfouling properties.

The zwitterionic crosslinker of the invention has excellentcompatibility with zwitterionic hydrogel systems. A representativecrosslinker, CBMAX, has a structure that corresponds to a usefulzwitterionic monomer, CBMA, which provides two advantageous effects.First, the zwitterionic nature of the crosslinker means that, inaddition to the improved solubility, the crosslinker does not interruptthe restructuring of water that occurs around the zwitterionic monomersidechains. Compared to hydrogels crosslinked with MBAA,CBMAX-crosslinked hydrogels exhibited improved nonfouling at allcompositions accessible to MBAA-crosslinked hydrogels, and ultimatelydemonstrated only about 10% of the nonspecific protein adsorption ofpHEMA hydrogels. Second, the chemical similarity between the CBMAmonomer and CBMAX crosslinker provides great polymerizationcompatibility. CBMAX-crosslinked hydrogels showed apparentstoichiometric incorporation of monomers and crosslinker. On the otherhand, as MBAA-crosslinked hydrogels reached the solubility limit ofMBAA, the relationship between crosslinker content and compressivemodulus began to fail. Thus, CBMAX-crosslinked hydrogels exhibitedgreatly improved mechanical properties relative to MBAA-crosslinkedhydrogels at the same nominal crosslinker content. The water solubilityof the CBMAX crosslinker, additionally, allows access to a much widerrange of formulations than were previously possible. Hydrogels made bypolymerizing only the crosslinker (in the absence of monomer) were foundto have high water content (60%), excellent nonfouling properties (about90% lower nonspecific cell adhesion than the nonfouling pHEMA controlhydrogel), and high mechanical strength (compressive modulus of about 8MPa). Furthermore, these hydrogels composed of the CBMAX crosslinker,like those made with the CBMA monomer, are functionalizable by means ofsimple EDC/sulfoNHS chemistry.

The follow examples are provided for the purpose of illustrating, notlimiting, the invention.

EXAMPLES

Materials. N,N′-Methylenebis(acrylamide), ammonium persulfate, sodiummetabisulfite, 2-(N-morpholino)ethanesulfonic acid (MES), methacrylicacid, ion exchange resin (IRA 400 OH form), and phosphate-bufferedsaline were purchased from Sigma Aldrich (St. Louis, Mo.). Ethanol waspurchased from Decon Labs (King of Prussia, Pa.), acetonitrile anddiethyl ether from EMD Biosciences (Gibbstown, N.J.), ethylene glycolfrom VWR (West Chester, Pa.), tetraethylene glycol dimethacrylate fromPolysciences (Warrington, Pa.), 2-hydrolxyethyl methacrylate, t-butylbromoacetate, and N-cyclohexyl-2-aminoethanesulfonic acid (CHES) fromTCI America (Portland, Oreg.), and N,N,N′,N′-tetramethylethylenediamine(TEMED) from Bio-Rad Laboratories (Hercules, Calif.).N-Methyldiethanolamine, triethanolamine, methanesulfonic acid, andtrifluoroacetic acid were purchased from Acros Organics (Morris Plains,N.J.). Dulbecco's Modified Eagle Medium, fetal bovine serum,nonessential amino acids, and penicillin-streptomycin were purchasedfrom Invitrogen Corp (Carlsbad, Calif.).Cyclo(arginine-glycine-asparginine-D-tyronsine-lysine) peptide (cRGD)was purchased from Peptides International (Louisville, Ky.). Hydrogenperoxide and sodium chloride salt were purchased from J. T. Baker(Phillipsburg, N.J.), and ImmunoPure® o-Phenylenediamine dihydrochloridewas purchased from Pierce (Rockford, Ill.). Horseradish peroxidase(HRP)-conjugated anti-fibrinogen was purchased from US Biological(Swampscott, Mass.). COS-7 cells (African Green Monkey fibroblast cells)were purchased from the American Tissue Culture Collection (Manassas,Va.). All water used had been purified to 18.2 mΩ on a MilliporeSimplicity water purification system.

Example 1 The Preparation of Representative Zwitterionic Crosslinkers:1-Carboxy-N-methyl-N-di(2-methacryloyloxy-ethyl)methanaminium Inner Salt(CBMX) and 1-Carboxy-N-tri(2-methacryloyloxy-ethyl)methanaminium InnerSalt (CBMA3X)

In this example, the preparation of representative zwitterioniccrosslinkers of the invention,1-carboxy-N-methyl-N-di(2-methacryloyloxy-ethyl)methanaminium inner salt(CBMX) and 1-carboxy-N-tri(2-methacryloyloxy-ethyl)methanaminium innersalt (CBMA3X), are described. The preparations are illustrated in FIG.2.

N-Methyl-N-di(ethanolamine methacrylate) (1)

N-Methyldiethanolamine (11.9 g, 0.1 mol), toluene (100 ml), hydroquinone(2.0 g), and methacrylic acid (21.5 g, 0.25 mol) were added to a 500 mlreaction flask fitted with a stirrer, condenser, and Dean-Star trap.Methanesulfonic acid (14.4 g, 0.15 mol) was added slowly and the mixturewas heated to reflux. After the theoretical water of reaction wascollected azeotropically, the solution was cooled to room temperature.The mixture was then neutralized with 25 wt % aqueous sodium hydroxideand the organic phase was washed with 10% brine solution and dried overanhydrous magnesium sulfate. The solution was filtered, and the filtratewas further treated with activated carbon and basic alumina. Theresulting solution was removed under vacuum to give a colorless oil with73% yield. ¹H-NMR (CDCl₃) δ: 6.10 (s, 2H), 5.56 (s, 2H), 4.25 (t, J=6.0Hz, 4H), 2.78 (t, J=6.0 Hz, 4H), 2.39 (s, 3H), 1.94 (s, 6H).

N-Methyl-N-di(2-methacryloyloxy-ethyl)-N-1-(t-butyloxycarbonylmethyl)ammoniumbromide (2)

Compound (1) (12.75 g, 50 mmol), t-butyl bromoacetate (11.70 g, 60mmol), acetonitrile (100 ml) were mixed in a nitrogen-filled flask. Themixture was stirred at 60° C. for 2 days. The solvent was evaporatedunder vacuum and the residue was washed with ether and dried to obtain awhite solid with 90% yield. ¹H-NMR (CDCl₃) δ: 6.15 (s, 2H), 5.67 (s,2H), 4.80 (s, 2H), 4.73 (t, J=6.0 Hz, 4H), 4.47 (m, 4H), 3.75 (s, 3H),1.95 (s, 6H), 1.48 (s, 9H).

1-Carboxy-N-methyl-N-di(2-methacryloyloxy-ethyl)methanaminium inner salt(3) (CBMAX)

The t-butyl ester moiety of compound (2) (13.5 g, 30 mmol) was removedby treatment with trifluoroacetic acid (TFA, 30 ml) in dichloromethane(120 ml) for 2 days at room temperature. The solvent was removed undervacuum and replaced with acetonitrile (120 ml). The solution wasneutralized over an ion exchange resin (IRA 400 OH form), subsequentlyconcentrated and precipitated into ether, and finally vacuum dried toobtain a white solid with quantitative yield. ¹H-NMR (D₂O) δ: 6.05 (s,2H), 5.66 (s, 2H), 4.56 (t, 4H), 4.20 (m, 2H), 3.95 (m, 4H), 3.24 (s,3H), 1.83 (s, 6H).

1-Carboxy-N-tri(2-methacryloyloxy-ethyl)methanaminium inner salt (4)(CBMA3X)

Compound (4) was prepared using a similar method as CBMAX, fromtriethanolamine and methacrylic acid to give to N-tri(ethanolaminemethacrylate), then react with t-butyl bromoacetate to giveN-tri(2-methacryloyloxy-ethyl)-N-1-(t-butyloxycarbonylmethyl)ammoniumbromide. After removal of the t-butyl ester moiety to obtain compound 4as a white solid. ¹H-NMR (D₂O) δ: 6.07 (s, 3H), 5.70 (s, 3H), 4.60 (t,6H), 4.20 (t, 6H), 4.04 (s, 2H), 1.85 (s, 9H).

Example 2 The Preparation and Properties of Representative ZwitterionicCrosslinked Hydrogels: CBMA/CBMAX

In this example, the preparation of representative zwitterioniccrosslinked hydrogels of the invention, CBMA/CBMAX, is described. Theproperties of a zwitterionic CBMAX-crosslinked hydrogel (CBMA/CBMAX)were compared to a zwitterionic MBAA-crosslinked hydrogel (CBMA/MBAA).

2-Carboxy-N,N-dimethyl-N-(2′-(methacryloyloxy)ethyl)ethanaminium innersalt (carboxybetaine methacrylate, CBMA) was synthesized as described inZhang Z, Chao T, Chen S, Jiang S. Superlow fouling sulfobetaine andcarboxybetaine polymers on glass slides. Langmuir 2006; 22(24):10072-10077.

Hydrogel Preparation

Monomer solutions were prepared in 1M NaCl, at a monomer concentrationof 65% by weight. To these solutions, the crosslinkers(N′,N′-methylenebis(acrylamide) (MBAA) or CBMAX (prepared as describedin Example 1) was added at amounts ranging from 2-23% (molar percent ofmonomer). CBMAX formulations above this were prepared up to 75% bymaintaining a constant total molar amount of monomer and crosslinker,and adjusting their relative molar amounts. 100% CBMAX was simplyprepared by dissolving the desired amount of CBMAX in 1M NaCl. Thesolutions were mixed by sonication. In some cases (above about 10%MBAA), the crosslinker did not dissolve completely. A 40% solution ofammonium persulfate and 15% sodium metabisulfite were added to thesolution to initiate polymerization. The solutions were polymerizedbetween glass microscope slides separated by 0.5 or 2 mm-thickpolytetrafluoroethylene (PTFE) spacers at 60° C. The gels were thenremoved from the slides and immersed in phosphate-buffered saline (PBS)to hydrate. This hydration water was changed daily for 5 days to removeunreacted chemicals and excess salt. Biopsy punches were used to punchhydrated hydrogels into 5 mm-diameter disks. HEMA hydrogels wereprepared by mixing 0.78 ml HEMA monomer in 1.5 ml of a mixed solventcomprised of 1 part ethanol, 1.5 parts ethylene glycol, and 1.5 partswater. The crosslinker, tetraethylene glycol dimethacrylate (TEGDMA),was then added (60 μl), and the resulting solution was sonicated to mixwell. Finally, 24 μl 40% ammonium persulfate and 7.5 μl TEMED wereadded. This hydrogel was formed as described above.

Swelling Properties of Hydrogels

Hydrogels were allowed to swell to equilibrium in PBS for five days.Disks with 0.5-cm diameter were cut from the swollen gel cast at 0.5 mmthickness. The disks were weighed and then dehydrated under vacuum at50° C. and 30 in. Hg vacuum for 3 days. Dried hydrogel disks weremeasured with a caliper and weighed. The volume fraction (Φ) of polymerwithin a swollen hydrogel is given by:

$\begin{matrix}{f_{2} = \left( \frac{D_{o}}{D} \right)^{3}} & (1)\end{matrix}$

where D_(o) and D are the diameters of dried and swollen disks,respectively. The volume fraction of polymer in the relaxed (unswollen)hydrogel, φ_(o), was determined from the monomer/crosslinker solutions.The volume of the solution was compared to the volume of water added.The difference in volume was taken as the volume of monomer, whichcorresponds to the volume of polymer after polymerization.

The equilibrium water content values were determined as:

$\begin{matrix}{{EWC} = {100(\%)*\frac{m_{w} - m_{d}}{m_{w}}}} & (2)\end{matrix}$

where m_(w) is the mass of the wet hydrogel and m_(d) is the mass of thedry hydrogel.

All samples were measured in triplicate.

Protein Adsorption Evaluated by Enzyme-Linked Immunosorbent Assay(ELISA)

To measure fibrinogen adsorption, hydrogel disks of 0.5 cm diameter (0.5mm thickness when cast) were incubated with 1 mg/ml fibrinogen in a wellplate for 15 minutes at room temperature followed by washes with PBSbuffer over 4 hours. The hydrogels were then removed from the last PBSwash and transferred to new wells. They were next incubated with a1:500-dilution of horseradish peroxidase (HRP)-conjugatedanti-fibrinogen in PBS for 10 minutes followed by another 5 washes withthe same buffer. The hydrogels were then washed repeatedly with PBSbuffer for 4 hours, removed from the last wash, and transferred to newwells. Finally, 500 μl 1 mg/ml o-phenylenediamine hydrochloride (OPD) in0.1 M citrate-phosphate buffer, pH 5.0, containing 0.03% hydrogenperoxide, was added to each hydrogel at 30-second intervals. The samplesincubated in the OPD solution for 30 minutes away from light. Thesupernatant was removed from each hydrogel disk, transferred to acuvette, and its absorbance at 492 nm was measured. All samples weremeasured in triplicate.

Cell Adhesion to Hydrogels

Three hydrogel disks of 0.5 cm diameter (0.5 mm thickness when cast)were placed individually in the wells of a 48-well plate with 500 ul PBSsolution. To sterilize the hydrogels, they were irradiated with UV lightfor 30 minutes and refrigerated overnight in 1× penicillin-streptomycinin PBS. COS-7 cells (p=7) were seeded onto the hydrogels at aconcentration of 10⁴ cells/ml in supplemented Dulbecco's Modified EagleMedium. Cells were allowed to grow for 72 hours at 37° C., 5% CO₂, and100% humidity, after which time the hydrogels were photographed at 10×magnification on a Nikon Eclipse TE2000-U microscope. Photographs weretaken at five predetermined areas on the surface of the hydrogel, for atotal of fifteen images per hydrogel formulation, and the number ofadherent cells from each image was totaled and normalized to the numberof cells adhered to pHEMA hydrogels.

RGD Functionalization Via EDC/sulfoNHS Chemistry

CBMA/MBAA and CBMA/CBMAX gels were functionalized with cRGD. Threehydrogel disks of 0.5 cm diameter (0.5 mm thickness when cast) wereplaced in the wells of a 24-well plate. All gels of each formulationwere split into two groups. The gels of each group were placed in thesame well, with care taken to ensure that the surface of each hydrogelwas uncovered. The hydrogels were incubated in 500 ul MES buffersolution (pH=5.5, 10 mM MES, 100 mM NaCl) overnight. The MES was thenremoved from one group of each formulation and replaced with 500 μl ofan MES-based buffer solution containing 5 mM sulfoNHS and 100 mM EDC, toactivate the surface, for 2 hours at room temperature. As a control, thesecond group of each formulation was incubated with an MES-based buffersolution of 5 mM sulfoNHS, for the same amount of time. The EDC/sulfoNHSand sulfoNHS solutions were then removed from the wells, and thehydrogel disks were washed three times with MES buffer. To all wells wasnext added 500 μl 1.4 mM cRGD in CHES buffer (pH=9, 50 mM CHES, 100 mMNaCl), and the reaction was allowed to proceed at room temperature.After 3 hours, the hydrogels were washed three times with PBS, allowing10 minutes per wash. Finally, hydrogels were transferred to individualwells of a 48-well polystyrene tissue culture plate, with care takenthat the functionalized surface remained facing upwards. The hydrogelswere sterilized with penicillin-streptomycin overnight as describedabove, and cell adhesion was performed the next day, also as describedabove.

Mechanical Strength of Hydrogels

At least five 0.5 cm diameter disks of each formulation (2 mm thicknesswhen cast) were compressed to failure at a rate of 1 mm/min using anInstron 5543A mechanical tester (Instron Corp., Norwood, Mass.) with a10N load cell. The Young's modulus was calculated from the initial 10%strain.

Calculation of Physical Properties of CBMA Hydrogels

Hydrogel hydration properties (swollen and relaxed volume fractions) andstress-strain curves can be used to calculate the crosslinker densityand mesh size of the different 2-arm CBMAX- and MBAA-crosslinkedhydrogel formulations. To calculate the crosslinker density (ν_(e)/V) ofhydrogels, the following equation was used:

$\begin{matrix}{\tau_{s} = {\left( \frac{v_{e}}{V} \right)\frac{{RT}\left( {\alpha - \alpha^{- 2}} \right)}{\left( {\varphi_{2}/\varphi_{0}} \right)^{2/3}}}} & (3)\end{matrix}$

where τ_(s) is the stress at a particular strain, in units of Pa, α isthe deformation ratio, or the ratio of the deformed length to theoriginal length of a crosslinked hydrogel under compression. R is theuniversal gas constant, T is absolute temperature, φ₂ is the volumefraction of polymer at equilibrium (in the fully swollen hydrogel), andφ_(o) is the volume fraction of polymer in the relaxed state (unswollen,but not dehydrated, hydrogel). A plot of τ_(s) vs (α−α⁻²) is linear atlow strain, and the crosslink density (ν_(e)/V) can be extracted fromthe slope (ν_(e)/V)(RT)(φ₂/φ_(o))⁻².

The crosslink density in moles/unit volume can be converted to distancebetween crosslinks, or mesh size, using equation (4):

$\begin{matrix}{\xi = \left( \frac{N_{A}v_{e}}{V} \right)^{1/3}} & (4)\end{matrix}$

where N_(A) is Avogadro's number. Equation (4) inverts moles/volume tovolume per mole, converts moles to number of crosslinks, and takes acube root to obtain distance per crosslink. This value is effectivelypore size of the hydrogel.

Example 3 The Preparation and Properties of a RepresentativeZwitterionic Crosslinked Hydrogels Prepared by Photopolymerization:CBMA/CBMAX

In this example, the preparation and properties of representativezwitterionic crosslinked hydrogels of the invention, CBMA/CBMAX,prepared by photopolymerization are described.

Preparation of CB-Based Hydrogels

Solutions of monomer and crosslinker were prepared in 1M NaCl, with 47%polymerizable material by weight. The crosslinker (CBMAX) was includedat amounts ranging from 2-80 mole % of monomer (CBMA). A solution for100% CBMAX was prepared by dissolving the desired amount of CBMAX in 1MNaCl, with 47 wt % CBMAX. All solutions were mixed by sonication in icewater. 1% (wt/wt) of photoinitiator,2-hydroxy-2-methyl-1-phenyl-1-propanone, was added to each solution andsonication in ice water was used to mix the solution thoroughly. Thesolutions were polymerized between glass microscope slides separated by1 mm-thick polytetrafluoroethylene (PTFE) spacers with UV irradiation,365 nm, for 30 minutes on each side. The gels were then removed from theslides and immersed in PBS to hydrate. This hydration water was changeddaily for 5 days to remove unreacted chemicals and excess salt. Biopsypunches were used to punch hydrated hydrogels into 5 mm-diameter disks.

Hydration Properties of Hydrogels

Swollen hydrogel disks were equilibrated in PBS for five days. 0.5 cmdisks were cut from the fully hydrated hydrogel slabs and weighed. Thedisks were then dehydrated in a vacuum oven at 45° C. and 30 in. Hgvacuum for 3 days. The swelling ratios were determined by the ratio ofthe swollen hydrogel weight to the dry hydrogel weight and theequilibrium water content (EWC) of each disk was determined asEWC=100(%)*(m_(w)−m_(d))/m_(w), where m_(w), is the mass of the wethydrogel and m_(d) is the mass of the dry hydrogel. All samples weremeasured in triplicate. EWC values for CBMA-CBMAX hydrogels with varyingCBMAX content are shown in FIG. 7. As the gels become more crosslinked,the EWC decreases until reaching a steady value of approximately 51% forgels containing more than 50 mol % CBMAX.

Compressive Properties of Hydrogels

At least three disks of 0.5 cm diameter (1 mm thickness when cast) werecompressed to failure at a rate of 1 mm/min using an Instron 5543Amechanical tester (Instron Corp., Norwood, Mass.) with a 10N load cell.The Young's modulus was calculated from the initial 10% strain. FIGS. 8and 9 show the compressive strength and modulus, respectively, ofCBMA-CBMAX hydrogels with varying CBMAX incorporation. The compressivestrength and modulus of the gels increase as crosslinker contentincreases. The trend in modulus is identical to hydrogels that aresynthesized via thermal initiation, however there is a 10-fold increasein value. The decreased modulus values for thermally polymerizedhydrogels could be due to inhomogeneities across the gel as a result ofheat transfer limitations during initiation. Pockets of inhomogeneitywill adversely affect mechanical properties. An alternate explanationfor the increase in modulus for photopolymerized gels could stem fromthe solubility of the photoinitiator. The photoinitiator is less watersoluble than the thermal initiator, so fewer polymer chains will beinitiated. This translates into longer polymer chains, which is the sameas having more crosslinks in hydrogels.

Cytotoxicity and Endotoxicity Testing of Hydrogels

The photopolymerized CBMAX-crosslinked CBMA hydrogels were tested toensure that they contain neither cytotoxic chemical features orendotoxin contamination. Materials prepared for in vivo implantationmust be free of endotoxins, which are bacterial residues from the cellwall of Gram-negative bacteria. In vitro bacterial residues areinconsequential, but in vivo they can trigger an immune response thatwill enhance the foreign-body response against the material and confoundthe results of in vivo testing.

To test for cytotoxicity, fully-hydrated hydrogel disks were soaked insupplemented growth medium (89% Dulbecco's Modified Eagle Medium, 10%fetal bovine serum, 1% penicillin-streptomycin, and 1× non-essentialamino acids) for 24 hours, whereupon the medium was removed from thehydrogels and used to culture COS-7 cells that had been plated and grownin fresh supplemented medium 24 hours prior. The cells were thenincubated with the hydrogel-infused supplemented medium for a further 48hours, and their morphology was analyzed as an indicator of cellproliferation and health. It was found that all of the cell populationsdisplayed the same degree of proliferation and health whether they wereincubated with hydrogel-infused medium or with a fresh medium control.

To test for endotoxin contamination, a Limulus Amebocyte Lysate (LAL)endotoxin test was performed, following a standard procedure. Sampleswere extracted with LAL-free water for several days and the water wasthen tested for the presence of endotoxins using an enzymatic assay withsensitivity to detect endotoxins above 0.06 EU/ml (Lonza). In thepresence of endotoxins at concentrations this detection limit, theenzyme assay solution will crosslink itself to form a gel, but gelationwill not occur at endotoxin levels below this concentration. Standardswere tested alongside the samples to validate the results. The gelationassay revealed that all of the hydrogels tested were free of endotoxins.

Example 4 The Preparation and Properties of a RepresentativeZwitterionic Crosslinked Hydrogels Prepared by PhotopolymerizationHaving Crosslinking Gradients: CBMA/CBMAX

In this example, the preparation and properties of representativezwitterionic crosslinked hydrogels of the invention, CBMA/CBMAX,prepared by photopolymerization and having crosslinking gradients aredescribed.

Hydrogel Preparation

A monomer (CBMA) solution was prepared in 1M NaCl, at a concentration of65% by weight. This solution was mixed with sonication and chilled.Photoinitiator, same as used above, was added to the monomer solution,and the monomer-initiator solution was loaded as-is between twomicroscope slides separated by a 2 mm-thick polytetrafluoroethylene(PTFE) spacer. Next, a 65%-by-weight solution of crosslinker (CBMAX) wasprepared similarly, and also sonicated and chilled. This solution wascarefully added to the monomer solution after the latter was loaded intothe microscope slide apparatus. Due to different solution densities, thecrosslinker solution appeared to settle to the bottom of the apparatusbefore diffusion created a crosslinker gradient. Visual observation ofthis phenomenon was made possible by trace amounts of colored materialin the crosslinker. This process is illustrated in FIG. 10. Finally, butbefore diffusion homogenized the solution, polymerization was initiatedby long wave UV light for 30 minutes, after which time the hydrogels wasremoved from the glass slides and hydrated in PBS for 5 days.

Gradient Analysis

The crosslinking profile of the gradient hydrogels was assayed bymeasuring the equilibrium water content along the length of the hydrogelslab. 5-mm disks were cut from contiguous sections along the edge of thegel, from the region of highest crosslinker concentration (more darklycolored, see FIG. 10) to the region of lowest crosslinker concentration.The disks were weighed, thoroughly dehydrated for 3 days at 50° C. and30 in. Hg vacuum, and reweighed. The equilibrium water content of eachdisk was determined as EWC=100(%)*(m_(w)−m_(d))/m_(w), where m_(w) isthe mass of the wet hydrogel and m_(d) is the mass of the dry hydrogel.

Hydrogel Characterization

Previously, equilibrium water content was measured for CBMA hydrogelswith different CBMAX concentrations, ranging from 2% CBMAX to 100%CBMAX. Using this established relationship, it is possible to convertthe equilibrium water content measured at different locations on thesame CBMA/CBMAX hydrogel to CBMAX concentration at each particularlocation. Furthermore, using results from the extensive characterizationof physical and mechanical properties performed in the precedingchapter, the crosslinker content profile can be correlated to itscorresponding mechanical (compressive) modulus, mesh size, andcrosslinking density (FIGS. 11-14).

Gradient Hydrogel Formation and Analysis

The gradient gel was formed as described above. Due to a colored tracerincluded in the crosslinker, the gradient was visible to the naked eye(FIG. 15). The equilibrium water content was converted to crosslinkercontent using the relationship shown in FIG. 11. The crosslinker contentas a function of distance along the gel starting at the highestcrosslinker edge is shown in FIG. 16. The crosslinker content rangesfrom around 100% to 30%, with a fairly uniform gradient in theintermediate region, indicating successful formation of a singlematerial with higher concentration of crosslinker at one end.

The hydrogel was made with diverse and spacially controlled properties.The crosslinker content ranges from around 100% to 30%, with a fairlyuniform gradient in the intermediate region. Because the materials used,CBMA monomer and CBMA crosslinker, have identical backbone andside-chains, the overall hydrogel is composed essentially of a singlematerial. Thus, the gradient in water content, crosslinker density, andmesh pore size did not compromise the continuity of certain desiredproperties, such as nonfouling and functionalizability.

The hydrogel is made from a single material and displays a uniformgradient of crosslinking and the corresponding physical, mechanical andhydration properties. The monomer and crosslinker differ from each otheronly by one or two methacrylate groups, and thus the entire structure iscomposed solely of zwitterionic carboxybetaine and methacrylate; thegradient is formed by a gradual increase in themethacrylate-to-zwitterionic ratio. Even at 100% crosslinker (2:1methacrylate-to-zwitterionic), the hydrogel demonstrated 90% lowernonspecific cell adhesion than nonfouling pHEMA hydrogels and goodfunctionalization. Thus, along the entire gradient, despite decreases inmechanical strength and crosslinker density and increases in pore sizeand hydration, the material remains zwitterionic and functionalizable,rendering the bioactivity of the gel controllable.

Example 5 Zwitterionic Poly(carboxybetaine) Hydrogels for GlucoseBiosensor

In this example, the use of a representative zwitterionic crosslinkedhydrogel of the invention, CBMA/CBMAX, in a glucose biosensor isdescribed.

Preparation of polyCBMA Hydrogels.

CBMA monomer was first mixed with water and the solution was sonicatedfor 1 min to dissolve the monomer. CBMAX was added to the above solutionand the mixture was sonicated for 1 min to complete dissolution at 0° C.The molar ratio of CBMA and CBMAX was 1000:1, 100:1, 10:1, and 5:1 andthe final concentration of CBMA was 10 M. 1% (w/w) Photoinitiator(Benacure 1173) was added and the solutions mixed at 0° C. The solutionswere transferred into a pair of glass plates, separated with a 0.4 mmPTFE spacer. The photopolymerization reaction was carried out at roomtemperature for 30 min under a 365 nm UV light to polymerize thehydrogels. Then, the hydrogels were removed from the plates and immersedin a large volume of PBS. The PBS was changed daily for 5 days to removeresidual chemicals before further use.

Analysis of Mechanical and Cell Adhesion Properties of Hydrogels.

Hydrogels were allowed to swell to equilibrium in PBS buffer for fivedays. The equilibrated hydrogels were then punched into disks with adiameter of 5 mm. The disks were weighed and then dehydrated undervacuum at 50° C. and 30 in. Hg vacuum for 3 days. The swelling ratioswere determined by the ratio of the swollen hydrogels weight to the dryhydrogels weight and the equilibrium water content values weredetermined as described above. All samples were measured in triplicate.As shown in FIG. 17, the highest water content was obtained for 0.1%CBMAX hydrogels, which was 94.19±0.26%. With the increase of the CBMAXmolar ratio, the water content decreased.

Three hydrogel disks of 5 mm diameter (0.5 mm thickness when cast) wereplaced individually in the wells of a 48-well plate with 500 μL PBSsolution. To sterilize the hydrogels, they were refrigerated overnightin 1× penicillin-streptomycin in PBS. COS-7 cells (p=7) were seeded ontothe hydrogels at a concentration of 1×10⁴ cells/mL in supplemented DMEM.Cells were allowed to grow for 72 hours at 37° C., 5% CO₂, and 100%humidity, after which time the hydrogels were photographed at 10×magnification with a Nikon Eclipse TE2000-U microscope. Photographs weretaken at five predetermined areas on the surface of the hydrogels, for atotal of fifteen images per hydrogel formulation. The difference in cellbinding on the surface of different CBMAX molar ratio polyCBMA hydrogelsbefore and after GOx immobilization is shown quantitatively in FIGS.18A-18H. All the polyCBMA hydrogels except 10% CBMAX molar ratiohydrogels were highly resistant to cell attachment before and after GOximmobilization; there was an extremely low amount of cell adhesion tothe surface.

Preparation of polyCBMA Hydrogel-Coated Glucose Sensors.

Glucose sensors were based on the coil-type implantable sensor. Thecoil-type glucose biosensors were prepared by winding the top 10 mm of a40-50 mm long platinum wire along a 25-gauge needle to form a coil-likecylinder. To improve the adhesion of the polyCBMA hydrogels, the surfaceof the coils was functionalized using a solution of 10%(trimethoxysilyl)propyl methacrylate and 0.5% water in toluene at 80° C.For formation of the hydrogel coating on the glucose sensor tip, 1.2 μLof the mixed solution (CBMA, CBMAX, and photoinitiator along with water)was pipetted onto the sensor tip. The solution was allowed to spreadevenly over the surface of the tip. After exposing to 254 nm UV lightfor 30 min, the sensors (referred to as Pt/CBMA/GOx) were stored in PBSuntil further use.

Enzyme Immobilization Via NHS/EDC Chemistry.

The carboxylate groups of the polyCBAA hydrogel were activated byinjection of a freshly prepared solution of N-hydroxysulfosuccinimidesodium (5 mM) and N-ethyl-N′-(3-diethylaminopropyl) carbodiimidehydrochloride(EDC) (100 mM) in 10 mM MES buffer (pH 5.5, 100 mM NaCl)for 2 h at 25° C. Then, the sensors were removed and immersed in a largevolume of the above MES buffer for 2 h. The MES buffer was changedseveral times to remove residual chemicals. The sensors were immersed ina freshly prepared solution of glucose oxidase (GOx) (10 mg/mL) in MESbuffer for 4 h at 4° C. followed with a freshly prepared solution ofglucose oxidase (GOx) (1 mg/mL) in PBS buffer for 2 h at 4° C. Beforefurther glucose test, the sensors were immersed in a large volume of PBSto remove all unsteady binding.

Sensor Evaluation In Vitro.

The in vitro performance of the sensors was examined in glucose PBSsolution to determine sensitivity and linear range of sensors. Thesensitivity of the Pt/CBMA/GOx sensors was first measured using 4 and 20mM glucose PBS solution. The difference between the base current of PBSand the steady state current of glucose in the sample was used to obtainthe calibration graph. Then, the sensors were examined with glucosesolution dispersed in 100% human blood serum. For the long-term sensorevaluation, the sensors were dipped into 100% human blood serum at 4° C.before the next test at different incubating days. When determiningglucose in a serum sample, the base current was taken in the serum andthen the sensor was transferred into the sample to obtain a steady statecurrent. All experiments were carried out at room temperature and allthe solution was stirred during the measurement. Amperometricmeasurements were performed at room temperature at +0.75 V vs. Ag/AgCland a platinum wire counter electrode. The current responses of glucosesensors coated with different CBMAX molar ratio polyCBMA hydrogels as afunction of glucose concentration in PBS are compared in FIGS. 19A-19D.All the sensors display very high sensitivity and current response toglucose in PBS. Furthermore, their response did not delay with excellentlinearity over the 4-20 mM range. The current responses of glucosesensors coated with different CBMAX molar ratio polyCBMA hydrogels as afunction of glucose concentration in 100% blood serum are compared inFIGS. 20A-20D. The sensors coated with 0.1% CBMAX molar ratio polyCBMAhydrogels did not show a decline in either sensitivity or linearityafter exposure to blood samples over 10 days while the other sensorsfailed to perform well. The result suggests that the addition ofpolyCBMA hydrogel coating improves the long-term performance of theimplanted glucose sensors.

Example 6 Zwitterionic Poly(Carboxybetaine) Hydrogels for GoldNanoparticles

In this example, the use of a representative zwitterionic crosslinkedhydrogel of the invention, CBMA/CBMAX, in a glucose biosensor isdescribed.

Synthesis of Initiator-Modified Gold Nanoparticles (GNPs).

5 mM aqueous solution of either HAuCl₄ (30 mL) was added to a 4 mMsolution of tetraoctylammonium bromide (TOAB) in toluene (80 mL) understirring for 10 min. Aqueous solution NaBH₄ (0.4 M, 25 mL) was thenadded dropwise to this solution while vigorously stirring. The darkorange solution turned red within a minute, and the stirring wascontinued for 3 h to make sure the reaction was complete. Then the twophases were separated, and the organic phase was subsequently washedwith 0.1 M H₂SO₄, 0.1 M NaOH, and water (three times each). Then,initiator, 274.2 mg of 11-mercaptoundecyl 2-bromoisobutyrate(Br(CH₃)₂COO(CH₂)₁₁SH) (0.808 mmol, dissolved in 1 mL toluene) wereadded to the solution in a dropwise fashion within 15 min. The reactionwas allowed to proceed for overnight. Methanol (60 mL) was added to thesystem to precipitate the Au-NPs. The precipitate was collected andre-dispersed in toluene and precipitated again into ethanol. Thisprecipitation and re-dispersion cycle was repeated twice before the pureAu-NPs (i.e. free of reaction byproducts) were obtained. The NPs werewell dispersed in acetone without aggregation and the average diameterof the Au-NPs was about 5 nm.

Preparation of CBMA Coated GNPs Via ATRP (CA-GNPs).

300 mg CBMA monomer, 61.70 mg 2,2-bipyridine, and 28.53 mg copper(I)bromide were dissolved in 3 ml degassed acetone and 0.5 ml methanolunder nitrogen atmosphere. 1 mL initiator-modified GNPs solution wasdeoxygenated by bubbling nitrogen before mixed with above solution. Thefinal mixture was stirred (100 rpm) at room temperature for 2 h. Afterthe polymerization, CA-GNPs were washed several times bycentrifuging/redispersing in water. The average diameter of the CA-NPswas 69.8 nm in water.

Preparation of OEGMA Coated GNPs Via ATRP (OA-GNPs).

47.7 mg copper(I) bromide, 7.43 mg copper(II) bromide, and 104 mg2,2-bipyridine were dissolved in 4 ml degassed acetone under nitrogen. 1mL initiator-modified GNPs solution was deoxygenated by bubblingnitrogen before directly mixed with the above solution. 2 g macromonomerOEGMA was added and the final mixture was stirred at room temperaturefor 6 h. After the polymerization, OA-GNPs were washed several times bycentrifuging/redispersing in Milli-Q water. The average diameter of theOA-NPs was 72.4 nm in water.

Preparation of OEGMA Coated GNPs Via ATRP with Addition of EGDMACrosslinker (OC-GNPs).

47.7 mg copper(I) bromide, 7.43 mg copper(II) bromide, and 104 mg2,2-bipyridine were dissolved in 4 ml degassed acetone under nitrogen. 1mL initiator-modified GNPs solution was deoxygenated by bubblingnitrogen before directly mixed with the above solution. 2 g macromonomerOEGMA and 126.4 μL EGDMA was added and the final mixture was stirred at50° C. for 6 h. After the polymerization, OC-GNPs were washed severaltimes by centrifuging/redispersing in Milli-Q water. The averagediameter of the OC-NPs was 71.9 nm in water.

Preparation of CBMA Coated GNPs Via ATRP with Addition of CBMAXCrosslinker (CC-GNPs).

300 mg CBMA monomer, 3.0 mg CBMAX, 61.7 mg 2,2-bipyridine, 4.4 mgcopper(II) bromide and 28.533 mg copper(I) bromide were dissolved in 3ml degassed acetone and 0.5 ml methanol under nitrogen atmosphere. 1 mLinitiator-modified GNPs solution was deoxygenated by bubbling nitrogenbefore directly mixed with the above solution. The final mixture wasstirred at 50° C. for 6 h. After the polymerization, CCE-GNPs werewashed several times by centrifuging/redispersing in Milli-Q water. Theaverage diameter of the CC-NPs was 80 nm in water.

Stability Test of Polymer-Coated GNPs.

The stability of polymer-coated GNPs was further evaluated in 100% humanblood serum at 37° C. Due to high protein concentrations, thesenanoparticles were separated from human blood serum proteins bycentrifugation and re-dispersed in PBS buffer. The average diameter ofthe nanoparticles was then evaluated by DLS at 37° C. All the solutionswere mixed with 100% human blood serum at 37° C. before the next test atdifferent incubating time. As shown in FIG. 21, OA-GNPs showed a sizeincrease of about 50 nm in a very short period of time. At the end of 72h, the diameter increased to about 140 nm, indicating significantprotein adsorption and particulate aggregation. Although OC-GNPs werenot stable in such extreme situation, the addition of EGDMA helped toenhance the stability. The diameter increments were 6 nm and 30 nm afteran incubation period of 6 h and 72 h, respectively. Precipitates couldbe observed in the above solutions. However, three kinds of GNPs withthe protection of polyCBAA coating (CA-GNPs, CCE-GNPs, and CCC-GNPs),the interactions between proteins and nanoparticles did not cause anyagglomeration and the particle sizes after their separation from humanblood serum proteins was almost the same as those without serum (70 nm,50 nm and 105.9 nm), indicating their excellent stability.

Next, polymer-coated nanoparticles were mixed with human blood serum ata very high concentration and incubated at 37° C. The average diameterof the nanoparticles was then evaluated by DLS at 37° C. As shown inFIG. 22, the OA-GNPs showed an increase of about 20 nm in size after 6h. This value increased to 200 nm after 72 h, which was attributed tothe interactions of nanoparticles with proteins in the incubation serummedium. Again, the addition of EGDMA increased the stability. Thediameter increment was 70 nm after an incubation period of 72 h.However, with polyCBMA coating, there is no agglomeration and all threesamples showed good stability without obvious size increase during thetest period of 72 h.

While illustrative embodiments have been illustrated and described, itwill be appreciated that various changes can be made therein withoutdeparting from the spirit and scope of the invention.

The embodiments of the invention in which an exclusive property orprivilege is claimed are defined as follows:
 1. A compound representedby the formula:

wherein R₁ and R₂ are independently selected from the group consistingof hydrogen, fluorine, trifluoromethyl, C1-C6 alkyl, and C6-C12 arylgroups; R₃ is selected from the group consisting of C1-C6 alkyl, C6-C12aryl, CH₂═C(R₁)-L₁-, and CH₂═C(R₂)-L₂-; L₁ and L₂ are independentlyselected from the group consisting of —C(═O)O—(CH₂)_(n)— and—C(═O)NH—(CH₂)_(n)—, wherein n is an integer from 1 to 20; L₃ is—(CH₂)_(n)—, where n is an integer from 1 to 20; A₁ is C, S, SO, P, orPO; X⁻ is the counter ion associated with the N⁺ cationic center; and M⁺is a counterion associated with the (A₁=O)O⁻ anionic center.
 2. Thecompound of claim 1, wherein R₁, R₂, and R₃ are independently selectedfrom the group consisting of C1-C6 alkyl.
 3. The compound of claim 1,wherein L₁ and L₂ are —C(═O)O—(CH₂)_(n)—, wherein n is 1-6.
 4. Thecompound of claim 1, wherein L₃ is —(CH₂)_(n)—, where n is an integerfrom 1-6.
 5. The compound of claim 1, wherein A₁ is C or SO.
 6. Thecompound of claim 1, wherein M⁺ at each occurrence is a metal or organicion.
 7. The compound of claim 1, wherein X⁻ at each occurrence ishalide, carboxylate, alkylsulfonate, sulfate; nitrate, perchlorate,tetrafluoroborate, hexafluorophosphate, trifluoromethylsulfonate,bis(trifluoromethylsulfonyl)amide, lactate, or salicylate.